NASDAQ · PCRX
Pacira BioSciences, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for PCRX: Nov 05, 2026
Pacira BioSciences, Inc. Common Stock is expected to report earnings on 11/05/2026 before market open. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $0.47. The reported EPS for the same quarter last year was $0.46.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $0.47 | $0.47 | $0.47 | 2 |
| Dec 2026 | $0.57 | $0.68 | $0.47 | 2 |
| Mar 2027 | $0.41 | $0.45 | $0.38 | 2 |
| Jun 2027 | $0.42 | $0.53 | $0.31 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · Fintel · RTTNews · The Motley Fool- Zacks · Oct 29, 9:00 AM EDTPacira BioSciences (PCRX) Reports Next Week: Wall Street Expects Earnings GrowthPacira BioSciences (PCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Fintel · Oct 23, 2:32 AM EDTPacira BioSciences Consensus Price Target Increased 17.74% to $35.13The average one-year price target for Pacira BioSciences (NASDAQGS:PCRX) (DB:82P) has been revised to $35.13 / share. This is an increase of 17.74% from the prior estimate of $29.84 dated September 29, 2026. These figures represent aggregate analyst targets compiled from multiple
- Zacks · Oct 9, 9:37 AM EDTViatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain PortfolioVTRS is set to acquire PCRX for $1.65 billion in cash, adding two marketed pain therapies and a clinical-stage gene therapy candidate to expand its non-opioid pain portfolio.
- RTTNews · Oct 9, 6:29 AM EDTBiotech Stocks At 52-Week Highs – PCRX +44% On Acquisition News; MANE+14%, HAE+17%, CON, HSTM(RTTNews) – The following biotech stocks reached a 52-week high on October 8, 2026, driven by catalysts such as reports of an upcoming acquisition or upcoming financial reports.
- Fintel · Oct 8, 9:25 PM EDTJP Morgan Upgrades Pacira BioSciences to Neutral from UnderweightFintel reports that on October 8, 2026, JP Morgan upgraded their outlook for Pacira BioSciences (NASDAQGS:PCRX) (DB:82P) from Underweight to Neutral.Pacira BioSciences, Inc., based in the United States, operates within the pharmaceutical industry and is primarily focused on the d
- The Motley Fool · Oct 8, 11:33 AM EDTWhy Pacira BioSciences Skyrocketed TodayPacira BioSciences is being bought out by Viatrias.
- RTTNews · Oct 8, 8:34 AM EDTViatris Agrees To Acquire Pacira BioSciences In $1.65 Bln Cash Deal(RTTNews) – Thursday, Viatris Inc. (VTRS) announced an agreement to acquire all of the outstanding shares of common stock of Pacira BioSciences, Inc. (PCRX), a biopharmaceutical company focusing on innovative non-opioid pain therapies, for $36.50 per share in a cash deal.
- RTTNews · Oct 7, 8:53 AM EDTPacira BioSciences Reports Caregiver Survey Findings On Postsurgical Recovery(RTTNews) – Pacira BioSciences (PCRX) and Caregiver Action Network reported findings from the "Ready, Set, Recover" initiative examining family caregivers' experiences with surgery preparation, postsurgical pain management and recovery at home.
- Zacks · Oct 6, 9:30 AM EDTPCRX Expands Exparel Commercial Reach in Europe Through Molteni DealPacira expands Exparel's European reach through Molteni, adding new markets and revenue streams, with the first commercial sale in Europe expected in 2027.
- Fintel · Sep 24, 3:36 AM EDTOppenheimer Initiates Coverage of Pacira BioSciences with OutperformFintel reports that on September 23, 2026, Oppenheimer initiated coverage of Pacira BioSciences (NASDAQGS:PCRX) (DB:82P) with a Outperform recommendation.Pacira BioSciences, Inc., based in the United States, operates within the pharmaceutical industry and is primarily focused on
- Fintel · Sep 9, 6:50 PM EDTLeerink Partners Initiates Coverage of Pacira BioSciences at Market PerformFintel reports that on September 9, 2026, Leerink Partners initiated coverage of Pacira BioSciences (NASDAQGS:PCRX) with a Market Perform recommendation. Pacira BioSciences, Inc., based in the United States, operates within the pharmaceutical industry and is primarily focused on
- Zacks · Sep 4, 11:30 AM EDTWhy Is Sarepta Therapeutics (SRPT) Up 37% Since Last Earnings Report?Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Pacira BioSciences, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.